Technical Analysis for ONCT - Oncternal Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 6.08 5.74% 0.33
ONCT closed up 5.74 percent on Monday, November 11, 2019, on 2.26 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ONCT trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Earnings Movers Other 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 5.74%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.74%
Bollinger Band Squeeze Range Contraction 5.74%
Calm After Storm Range Contraction 5.74%

Older signals for ONCT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Solid Tumors Cancers Drug Development Hematologic Cancers Sarcoma
Is ONCT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.92
52 Week Low 3.43
Average Volume 22,894
200-Day Moving Average 6.5426
50-Day Moving Average 5.2774
20-Day Moving Average 5.6108
10-Day Moving Average 5.696
Average True Range 0.3478
ADX 31.66
+DI 29.4262
-DI 9.6367
Chandelier Exit (Long, 3 ATRs ) 5.1616
Chandelier Exit (Short, 3 ATRs ) 5.3034
Upper Bollinger Band 6.0383
Lower Bollinger Band 5.1833
Percent B (%b) 1.05
BandWidth 15.238469
MACD Line 0.21
MACD Signal Line 0.1662
MACD Histogram 0.0438
Fundamentals Value
Market Cap 97.63 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 0.00
Price-to-Book 14.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.64
Resistance 3 (R3) 6.60 6.39 6.54
Resistance 2 (R2) 6.39 6.25 6.40 6.51
Resistance 1 (R1) 6.23 6.16 6.31 6.27 6.48
Pivot Point 6.02 6.02 6.06 6.03 6.02
Support 1 (S1) 5.86 5.88 5.94 5.90 5.68
Support 2 (S2) 5.65 5.79 5.66 5.65
Support 3 (S3) 5.49 5.65 5.62
Support 4 (S4) 5.53